Presence of risk factors for thyroid cancer does not improve the performance of ultrasound screening for thyroid nodules in patients with obesity.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
30
03
2021
received:
14
01
2021
accepted:
31
03
2021
pubmed:
8
4
2021
medline:
10
7
2021
entrez:
7
4
2021
Statut:
ppublish
Résumé
It has been suggested, on a theoretical basis, that ultrasound screening of thyroid nodules in obese patients with additional risk factors (family history, chronic autoimmune thyroiditis or high thyrotropin) might be cost-effective for the early detection and treatment of thyroid cancer. The present study evaluates if this approach can be validated in a real clinical setting. Patients with obesity who attended hospital-based clinics were evaluated for risk factors of thyroid cancer and ultrasound screened for thyroid nodularity. Detected nodules were evaluated according to current guidelines. A total of 429 patients were evaluated (70.2% women, mean age 49.1 ± 11.0, mean body mass index 42.6 ± 5.8 kg/m The presence of known risk factors for thyroid cancer does not improve the performance of a US screening strategy aimed at the detection of thyroid nodules in obese patients. According to current guidelines, screening for thyroid nodules in obese patients is not recommended regardless of the presence of thyroid cancer risk factors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14211Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Renehan AG, Tyson M, Egger M, Heller R, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578.
Hidayat K, Du X. Shi: BM Body fatness at a young age and risks of eight types of cancer: systematic review and meta-analysis of observational studies. Obes Rev. 2018;19:1385-1394.
Ma J, Huang M, Wang L, Ye W, Tong Y, Wang H. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Monit. 2015;21:283-291.
Youssef MR, Reisner ASC, Attia AS, et al. Obesity and the prevention of thyroid cancer: Impact of body mass index and weight change on developing thyroid cancer - pooled results of 24 million cohorts. Oral Oncol. 2021;112:105085.
Wu C, Wang L, Chen W, Zou S, Yang A. Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer: a retrospective study. Medicine. 2017;96(9):e6202.
Dieringer P, Klass EM, Caine B, Smith-Gagen J. Associations between body mass and papillary thyroid cancer stage and tumor size: a population-based study. J Cancer Res Clin Oncol. 2015;141:93-98.
Trésallet C, Seman M, Tissier F, et al. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery. 2014;156:1145-1152.
Grani G, Lamartina L, Montesano T, et al. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. J Endocrinol Invest. 2019;42:85-90.
Gąsior-Perczak D, Pałyga I, Szymonek M, et al. The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. PLoS One. 2018;13(10):e0204668.
Matrone A, Ceccarini G, Beghini M, et al. Potential impact of BMI on the aggressiveness of presentation and clinical outcome of differentiated thyroid cancer. J Clin Endocrinol Metab. 2020;105:e1124-e1134.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for thyroid cancer. JAMA. 2017;317(18):1882-1887.
Clement SC, Kremer LCM, Verburg FA, et al. Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2018;63:28-39.
Yamashita S, Suzuki S, Suzuki S, Shimura H, Saenko V. Lessons from Fukushima latest findings of thyroid cancer after the Fukushima nuclear power plant accident. Thyroid. 2018;28:11-22.
Mukasa K, Noh JY, Kunii Y, et al. Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic screening in patients with autoimmune thyroid diseases. Thyroid. 2011;21:37-41.
Han JM, Kim TY, Jeon MJ, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol. 2013;168:879-886.
Chen Y, Zhu C, Chen Y, et al. The association of thyroid nodules with metabolic status: a cross-sectional SPECT-China study. Int J Endocrinol. 2018;6(2018):6853617.
Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol. 2020;182:G1-G32.
Pinsky PF. Principles of cancer screening. Surg Clin North Am. 2015;95:953-966.
Cham S, Zanocco K, Sturgeon C, Yeh MW, Harari A. Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective. Thyroid. 2014;24:975-986.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
Castells I, Pardo N, Videla S, et al. Healthcare impact of introduction of thyroid ultrasound in a thyroid nodule pathology unit. Endocrinol Nutr. 2013;60:53-59.
Cibas ES, Ali SZ. NCI Thyroid FNA State of the science conference. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658-665.
Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. Am Coll Radiol. 2017;14:587-595.
Lin JS, Bowles EJA, Williams SB, Morrison CC. Screening for thyroid cancer: updated evidence report and systematic review for the us preventive services task force. JAMA. 2017;317:1888-1903.
Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26:1535-1540.
O'Grady TJ, Gates MA, Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011. Int J Cancer. 2015;137:2664-2673.
Cronan JJ. Thyroid nodules: is it time to turn off the US machines? Radiology. 2008;247:602-604.
Morgan DJ, Dhruva SS, Wright SM, Korenstein D. Update on medical practices that should be Questioned in 2015. JAMA Intern Med. 2015;175:960-964.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534.
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
Giorda CB, Carnà P, Romeo F, Costa G, Tartaglino B, Gnavi R. Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. Eur J Endocrinol. 2017;176:533-542.
Dekelbab BH, Abou Ouf HA, Jain I. Prevalence of elevated thyroid-stimulating hormone levels in obese children and adolescents. Endocr Pract. 2010;16:187-190.
Valdés S, Maldonado-Araque C, Lago-Sampedro A, Lillo-Muñoz JA, Garcia-Fuentes E. Perez-Valero V, et al.: Reference values for TSH may be inadequate to define hypothyroidism in persons with morbid obesity: Di@bet.es study. Obesity (Silver Spring). 2017;25:788-793.
Mukasa K, Noh JY, Kunii Y, et al. Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic screening in patients with autoimmune thyroid diseases. Thyroid. 2011;21(1):37-41.
Azizi G, Keller JM, Lewis M, et al. Association of Hashimoto's thyroiditis with thyroid cancer. Endocr Relat Cancer. 2014;21:845-852.
Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809-814.
Del Rio P, Montana Montana C, Cozzani F, et al. Is there a correlation between thyroiditis and thyroid cancer? Endocrine. 2019;66:538-541.
Shi L, Li Y, Guan H, et al. Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1,870 Chinese patients with thyroid nodules. Endocr J. 2012;59:973-980.
Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol. 2010;316:165-171.
Allen N, Desai N, Song C, Yu J, Prasad U, Francis G. Clinical features may help to identify children and adolescents with greatest risk for thyroid nodules. J Endocrinol Invest. 2020;43:925-934.
Buscemi S, Massenti FM, Vasto S, et al. Association of obesity and diabetes with thyroid nodules. Endocrine. 2018;60:339-347.
Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, Durante C. Interobserver agreement of various thyroid imaging reporting and data systems. Endocr Connect. 2018;7:1-7.
Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391-397.
Nakamura H, Usa T, Motomura M, et al. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest. 2008;31:861-865.